Elanco Animal Health INC Form 4 insider transactions
NYSE
Ellen de Brabander, Executive Vice President at Elanco Animal Health, reported transactions involving company common stock.
NYSE
Director Kapila K. Anand acquired 600.7104 deferred stock units in Elanco Animal Health through a director fee deferral plan.
NYSE
Elanco Animal Health Inc.'s President and CEO, Jeffrey N. Simmons, acquired 117.887 deferred stock units.
NYSE
Elanco Animal Health Inc. Executive Vice President Rajeev A. Modi acquired 61.5901 deferred stock units, increasing his beneficial ownership to 9,072.9178 units.
NYSE
Elanco Animal Health Inc.'s EVP and CFO, Robert M. VanHimbergen, acquired 8.216 deferred stock units under a pre-arranged plan.
NYSE
Elanco Animal Health's Executive Vice President, Rajeev A. Modi, disposed of 4,392 shares of common stock to cover tax withholding obligations.
NYSE
Elanco Animal Health Inc.'s General Counsel and Corporate Secretary, Shiv O'Neill, reported a disposition of 4,738 common shares at $24.88 each, primarily for tax liability.
NYSE
Elanco Animal Health Inc.'s CEO, Jeffrey N. Simmons, disposed of 37,898 shares of common stock to cover tax liabilities at a price of $24.88 per share.
NYSE
Elanco Animal Health Inc. Executive Vice President Timothy J. Bettington reported the disposition of 4,695 common shares at $24.88 per share.
NYSE
An Elanco Animal Health Inc. executive disposed of 6,492 common shares to cover tax withholding obligations at a price of $24.88 per share.
NYSE
Elanco Animal Health's Executive Vice President, Jose Manuel Correia de Simas, reported a disposition of 3,371 common shares for tax liability purposes.
NYSE
Elanco Animal Health's Executive Vice President, Ellen de Brabander, disposed of 8,262 common shares in a pre-planned transaction for tax liability.
NYSE
An Elanco Animal Health Inc. executive disposed of 3,433 shares of common stock to cover tax liabilities related to equity compensation.
NYSE
Elanco Animal Health's EVP of Manufacturing and Quality, Grace McArdle, sold 4,322 shares of common stock to cover tax liabilities.
NYSE
Elanco Animal Health's Chief Accounting Officer, James M. Meer, disposed of 1,389 shares of common stock to cover tax withholding obligations.
NYSE
Elanco Animal Health's Chief Accounting Officer, James M. Meer, reported the acquisition of common stock and restricted stock units, increasing his beneficial ownership.
NYSE
Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reported significant acquisitions of common stock, restricted stock units, stock options, and deferred stock units.
NYSE
Elanco Animal Health Inc. Executive Vice President Ramiro Martin Cabral reported significant equity grants and a tax-related disposition of common stock.
NYSE
Elanco Animal Health Inc's EVP of Manufacturing and Quality, Grace McArdle, reported significant equity grants and option awards, alongside a disposition for tax purposes.
NYSE
Elanco Animal Health's EVP, David S. Kinard, received significant equity compensation, including restricted stock units and stock options, increasing his beneficial ownership.
NYSE
Elanco Animal Health's Executive Vice President, Ellen de Brabander, reported new equity grants and a disposition of shares for tax purposes.
NYSE
Elanco Animal Health Inc.'s Executive Vice President, Timothy J. Bettington, reported significant equity grants and option awards, alongside a tax-related stock disposition, under a pre-arranged trading plan.
NYSE
Elanco Animal Health's Executive Vice President, Rajeev A. Modi, acquired 56.6301 deferred stock units.
NYSE
Elanco Animal Health CEO Jeffrey N. Simmons acquired 110.8583 deferred stock units, increasing his beneficial ownership.
NYSE
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, acquired 7.6217 deferred stock units, increasing his beneficial ownership.
NYSE
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, acquired 7.5552 deferred stock units, increasing his beneficial ownership.
NYSE
Elanco Animal Health Inc.'s President and CEO, Jeffrey N. Simmons, acquired 109.8905 deferred stock units, increasing his direct beneficial ownership.
NYSE
Elanco Animal Health's Executive Vice President, Rajeev A. Modi, acquired 56.1357 deferred stock units.
NYSE
Elanco Animal Health CEO Jeffrey N. Simmons acquired 113.4934 deferred stock units, increasing his beneficial ownership to 18,959.0151 units.
NYSE
Elanco Animal Health's Executive Vice President, Rajeev A. Modi, acquired 57.9762 deferred stock units, increasing his beneficial ownership to 7,538.3256 units.